Treatment of acromegaly in the era of personalized and predictive medicine.

Abstract excerpt

Acromegaly is a chronic disorder usually diagnosed late in the disease evolution. Such delayed diagnosis, together with the inability to achieve the treatment goals of normalizing biochemical disease markers and controlling tumour mass may result in substantial morbidity and mortality. Somatostatin analogues (SSA) are accepted as first-line medical therapy or as second-line therapy in patients undergoing...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents, Hormonal
• Share to Arrestins
• Share to beta-Arrestins